New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings - 26/09/12
Summary |
The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib. Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance. In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclinical and clinical studies in multiple myeloma. Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents.
Le texte complet de cet article est disponible en PDF.Plan
Vol 9 - N° 12
P. 1157-1165 - décembre 2008 Retour au numéro
Article précédent
- Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up
- Klara Mosterd, Gertruud AM Krekels, Fred HM Nieman, Judith U Ostertag, Brigitte AB Essers, Carmen D Dirksen, Peter M Steijlen, Anton Vermeulen, HAM Neumann, Nicole WJ Kelleners-Smeets
- Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw
- Beatrice J Edwards, Mrinal Gounder, June M McKoy, Ian Boyd, Mathew Farrugia, Cesar Migliorati, Robert Marx, Salvatore Ruggiero, Meletios Dimopoulos, Dennis W Raisch, Seema Singhal, Ken Carson, Eniola Obadina, Steve Trifilio, Dennis West, Jayesh Mehta, Charles L Bennett
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?